{"id":66494,"date":"2026-05-27T21:32:59","date_gmt":"2026-05-27T13:32:59","guid":{"rendered":"https:\/\/flcube.com\/?p=66494"},"modified":"2026-05-27T21:33:00","modified_gmt":"2026-05-27T13:33:00","slug":"junshi-biosciences-completes-phase-iii-neotorch-study-of-toripalimab-in-perioperative-nsclc-plans-regulatory-filing","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66494","title":{"rendered":"Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shanghai Junshi Biosciences Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1877:HKG\">HKG: 1877<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688180:SHA\">SHA: 688180<\/a>) announced the completion of analysis from the <strong>randomized, double-blind, placebo-controlled, multicenter Phase III NEOTORCH study<\/strong> (NCT04158440) evaluating <strong>Loqtorzi (toripalimab)<\/strong> in combination with <strong>platinum-based doublet chemotherapy<\/strong> as <strong>perioperative treatment<\/strong> for patients with <strong>resectable stage II-III non-small cell lung cancer (NSCLC)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-results-neotorch-phase-iii\" class=\"wp-block-heading\">Clinical Trial Results \u2013 NEOTORCH Phase III<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Primary Endpoint<\/th><th>Population<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Event-Free Survival (EFS)<\/strong><\/td><td>Stage II-III NSCLC<\/td><td>Met protocol-prespecified superiority boundary<\/td><\/tr><tr><td><strong>Major Pathological Response Rate (MPR)<\/strong><\/td><td>Stage II-III NSCLC<\/td><td>Met protocol-prespecified superiority boundary<\/td><\/tr><tr><td><strong>Major Pathological Response Rate (MPR)<\/strong><\/td><td>Stage III NSCLC<\/td><td>Met protocol-prespecified superiority boundary<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-study-design-overview\" class=\"wp-block-heading\">Study Design Overview<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase:<\/strong> Phase III (randomized, double-blind, placebo-controlled, multicenter)<\/li>\n\n\n\n<li><strong>Study Identifier:<\/strong> NCT04158440 (NEOTORCH)<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Resectable stage II-III non-small cell lung cancer (NSCLC)<\/li>\n\n\n\n<li><strong>Treatment Regimen:<\/strong> Toripalimab + platinum-based doublet chemotherapy (perioperative)<\/li>\n\n\n\n<li><strong>Control Arm:<\/strong> Placebo + platinum-based doublet chemotherapy<\/li>\n\n\n\n<li><strong>Primary Endpoints:<\/strong> EFS and MPR rates across specified populations<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-toripalimab-loqtorzi-profile\" class=\"wp-block-heading\">Toripalimab (Loqtorzi) Profile<\/h2>\n\n\n\n<h3 id=\"h-regulatory-status-amp-approvals\" class=\"wp-block-heading\">Regulatory Status &amp; Approvals<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Milestone:<\/strong> First home-grown programmed-death (PD)-1 monoclonal antibody in China<\/li>\n\n\n\n<li><strong>Chinese Approvals:<\/strong> <strong>13 indication approvals<\/strong> in domestic market<\/li>\n\n\n\n<li><strong>International Approvals:<\/strong> Marketing authorization in <strong>United States, European Union, India, UK, Australia, Singapore<\/strong> and other markets<\/li>\n\n\n\n<li><strong>Global Development:<\/strong> Subject to <strong>40+ clinical studies<\/strong> worldwide covering <strong>15+ indications<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-therapeutic-applications\" class=\"wp-block-heading\">Therapeutic Applications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology Focus:<\/strong> Broad immuno-oncology platform across multiple tumor types<\/li>\n\n\n\n<li><strong>NSCLC Strategy:<\/strong> Expanding into perioperative setting to address curative-intent patient population<\/li>\n\n\n\n<li><strong>Combination Potential:<\/strong> Demonstrated synergy with chemotherapy backbone in multiple settings<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-significance-amp-market-opportunity\" class=\"wp-block-heading\">Strategic Significance &amp; Market Opportunity<\/h2>\n\n\n\n<h3 id=\"h-perioperative-nsclc-market\" class=\"wp-block-heading\">Perioperative NSCLC Market<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population:<\/strong> Approximately 30-40% of NSCLC patients present with resectable stage II-III disease<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Limited effective systemic therapies for perioperative management<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> Curative-intent setting commands premium pricing and high treatment adoption<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Early entrant in perioperative PD-1 combination space<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-regulatory-pathway\" class=\"wp-block-heading\">Regulatory Pathway<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Filing Timeline:<\/strong> Near-term regulatory submission planned with Chinese authorities<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> Positive data supports potential international regulatory filings<\/li>\n\n\n\n<li><strong>Accelerated Review:<\/strong> Potential priority review designation given unmet need in resectable NSCLC<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-commercial-impact\" class=\"wp-block-heading\">Commercial Impact<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Enhancement:<\/strong> 14th potential indication in China, strengthening domestic leadership<\/li>\n\n\n\n<li><strong>Revenue Diversification:<\/strong> Perioperative setting provides new revenue stream beyond metastatic disease<\/li>\n\n\n\n<li><strong>Standard of Care Potential:<\/strong> Could establish toripalimab + chemo as new standard for resectable NSCLC<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-positioning\" class=\"wp-block-heading\">Competitive Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Advantage:<\/strong> Among first PD-1 inhibitors to demonstrate perioperative efficacy in NSCLC<\/li>\n\n\n\n<li><strong>Chinese Innovation Leadership:<\/strong> Reinforces Junshi&#8217;s position as leading domestic immuno-oncology developer<\/li>\n\n\n\n<li><strong>Global Recognition:<\/strong> International approvals validate quality and efficacy of Chinese-developed biologic<\/li>\n\n\n\n<li><strong>Pipeline Depth:<\/strong> Extensive global development program provides multiple growth vectors beyond NSCLC<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-next-steps-amp-timeline\" class=\"wp-block-heading\">Next Steps &amp; Timeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Submission:<\/strong> Near-term filing with Chinese regulatory authorities<\/li>\n\n\n\n<li><strong>Data Publication:<\/strong> Peer-reviewed publication and presentation at major oncology conferences expected<\/li>\n\n\n\n<li><strong>International Filings:<\/strong> Potential regulatory submissions in key international markets following Chinese approval<\/li>\n\n\n\n<li><strong>Commercial Preparation:<\/strong> Market access and reimbursement planning underway<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory filings, clinical development timelines, and market expectations for toripalimab. Actual results may differ due to risks including regulatory decisions, competitive dynamics, market access challenges, and commercial execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688180_20260527_WY6K.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688180_20260527_WY6K.\"><\/object><a id=\"wp-block-file--media-88284c99-68cb-4a50-b5dc-c35fc26c584e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688180_20260527_WY6K.pdf\">688180_20260527_WY6K<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688180_20260527_WY6K.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-88284c99-68cb-4a50-b5dc-c35fc26c584e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced the completion of analysis from&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,899,296,18,900],"class_list":["post-66494","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-hkg-1877","tag-junshi-biosciences","tag-pd-1-l1","tag-sha-688180"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced the completion of analysis from the randomized, double-blind, placebo-controlled, multicenter Phase III NEOTORCH study (NCT04158440) evaluating Loqtorzi (toripalimab) in combination with platinum-based doublet chemotherapy as perioperative treatment for patients with resectable stage II-III non-small cell lung cancer (NSCLC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66494\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing\" \/>\n<meta property=\"og:description\" content=\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced the completion of analysis from the randomized, double-blind, placebo-controlled, multicenter Phase III NEOTORCH study (NCT04158440) evaluating Loqtorzi (toripalimab) in combination with platinum-based doublet chemotherapy as perioperative treatment for patients with resectable stage II-III non-small cell lung cancer (NSCLC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66494\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-27T13:32:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-27T13:33:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66494#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66494\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing\",\"datePublished\":\"2026-05-27T13:32:59+00:00\",\"dateModified\":\"2026-05-27T13:33:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66494\"},\"wordCount\":487,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"HKG: 1877\",\"Junshi Biosciences\",\"PD-1\\\/L1\",\"SHA: 688180\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66494#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66494\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66494\",\"name\":\"Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-27T13:32:59+00:00\",\"dateModified\":\"2026-05-27T13:33:00+00:00\",\"description\":\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced the completion of analysis from the randomized, double-blind, placebo-controlled, multicenter Phase III NEOTORCH study (NCT04158440) evaluating Loqtorzi (toripalimab) in combination with platinum-based doublet chemotherapy as perioperative treatment for patients with resectable stage II-III non-small cell lung cancer (NSCLC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66494#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66494\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66494#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced the completion of analysis from the randomized, double-blind, placebo-controlled, multicenter Phase III NEOTORCH study (NCT04158440) evaluating Loqtorzi (toripalimab) in combination with platinum-based doublet chemotherapy as perioperative treatment for patients with resectable stage II-III non-small cell lung cancer (NSCLC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66494","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing","og_description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced the completion of analysis from the randomized, double-blind, placebo-controlled, multicenter Phase III NEOTORCH study (NCT04158440) evaluating Loqtorzi (toripalimab) in combination with platinum-based doublet chemotherapy as perioperative treatment for patients with resectable stage II-III non-small cell lung cancer (NSCLC).","og_url":"https:\/\/flcube.com\/?p=66494","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-27T13:32:59+00:00","article_modified_time":"2026-05-27T13:33:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66494#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66494"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing","datePublished":"2026-05-27T13:32:59+00:00","dateModified":"2026-05-27T13:33:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66494"},"wordCount":487,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","HKG: 1877","Junshi Biosciences","PD-1\/L1","SHA: 688180"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66494#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66494","url":"https:\/\/flcube.com\/?p=66494","name":"Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-27T13:32:59+00:00","dateModified":"2026-05-27T13:33:00+00:00","description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced the completion of analysis from the randomized, double-blind, placebo-controlled, multicenter Phase III NEOTORCH study (NCT04158440) evaluating Loqtorzi (toripalimab) in combination with platinum-based doublet chemotherapy as perioperative treatment for patients with resectable stage II-III non-small cell lung cancer (NSCLC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66494#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66494"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66494#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66494","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66494"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66494\/revisions"}],"predecessor-version":[{"id":66496,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66494\/revisions\/66496"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66494"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66494"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66494"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}